查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年荷尔蒙避孕药市场预测：按产品类型、荷尔蒙、年龄层、性别、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1383396

2030 年荷尔蒙避孕药市场预测：按产品类型、荷尔蒙、年龄层、性别、最终用户和地区进行的全球分析

Hormonal Contraceptives Market Forecasts to 2030 - Global Analysis By Product Type, Hormone, Age Group, Gender, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球荷尔蒙避孕药市场规模为 183 亿美元，预计到 2030 年将达到 282 亿美元，预测期内年复合成长率为 6.3%。

作用于内分泌系统的避孕方法称为荷尔蒙避孕药。这些技术使用女性通常产生的荷尔蒙（例如黄体酮和雌激素）来防止排卵和怀孕。荷尔蒙避孕会改变子宫并降低怀孕的机会。荷尔蒙避孕药有型态，包括皮肤贴片、药丸、注射、手臂植入和子宫内避孕器。这些荷尔蒙避孕方法对于预防怀孕是可靠且安全的。超过 99% 的意外怀孕可以透过荷尔蒙避孕来避免。

根据世界卫生组织 (WHO) 的数据，现代避孕药具普及率从 1990 年的 54% 上升到 2015 年的 57.4%。

世界人口成长

世界人口持续成长，这种人口趋势导致对有效避孕方法的需求增加。荷尔蒙避孕药因其可逆性、方便性以及帮助人们控製家庭规模和延迟或间隔怀孕的有效性而受到欢迎。随着个人努力实现其理想的家庭规模并改善其经济状况，获得有效的避孕方法变得至关重要。这些因素正在推动市场需求。

相关副作用

潜在的缺点包括鹅口疮（阴道酵母菌感染疾病），以及头痛、噁心和乳房疼痛等副作用。除了在月经期间感到沮丧和出血外，荷尔蒙还会降低女性的性慾。此外，形成血栓（血栓症）的可能性很小。吸烟、极度超重和有血管疾病家族病史的女性比 40 岁以上的女性有更高的风险。因此，这些缺点可能会阻碍市场扩张。

创新

药物研究和开发的进步导致了新型和增强型荷尔蒙避孕药的推出。其中包括低剂量製剂、长效可逆避孕药 (LARC)，包括荷尔蒙子宫内避孕器和植入式植入，以及经皮经皮吸收贴片尖端给药方法。技术创新增加了消费者的选择并促进了市场的扩张。

法规政策及法规

市场可能会受到限制荷尔蒙避孕药供应和使用的法律法规的显着影响。在许多国家，严格的法规以及文化和宗教信仰限製或阻止荷尔蒙避孕药的使用。然而，这些限制可能会阻碍市场扩张，并限制需求者获得荷尔蒙避孕药。

COVID-19 的影响

由于疫情期间计划生育率下降以及避免意外怀孕的需要，COVID-19 对荷尔蒙避孕药市场总体产生了一定程度的负面影响。这些避孕药具主要用于计划生育。诊所关闭、预约取消和医护人员短缺可能会限制避孕药具的取得，尤其是荷尔蒙避孕药。这些准入限制可能会减少荷尔蒙避孕药的市场或增加低效避孕药的使用。

口服避孕药市场预计将在预测期内成为最大的市场

口服避孕药市场估计占最大份额。 OCP 已问世数十年，是最受欢迎的荷尔蒙避孕药之一。口服避孕药是寻求可靠避孕方法的人们的普遍选择，因为如果正确和持续使用，它们相当有效。此药的作用是抑制排卵、使子宫颈黏液变稠、削弱子宫内膜。每天服用口服避孕药。在大多数配方中，您服用的药丸有效期为 21 天，然后服用一週的无荷尔蒙药丸或安慰剂。

预计医院领域在预测期内的年复合成长率最高。

预计医院部门在预测期内将出现良好的成长。促进该行业成长的关键因素是对这些荷尔蒙避孕药的需求不断增长而未得到满足、新兴经济体中女性对不可逆避孕的偏好以及艾尔建和拜耳公司等公司的创新宫内避孕。其中包括设备的引进和多专科医院的发展。此外，改善医院药局的投资正在增加，特别是在开发中国家。

占比最高的地区

由于荷尔蒙避孕的高普及、该地区行业参与企业的强大影响力以及良好的医疗基础设施等因素，北美在预测期内获得了最大的市场占有率。在北美，荷尔蒙避孕组织非常完善。该地区受益于避孕方法的高接受度和知识，以及透过药房和保健医生合理、方便地获得荷尔蒙避孕药。北美市场上有多种避孕方法，包括口锭剂、贴片、注射和子宫内避孕器 (IUD)。

复合年复合成长率最高的地区：

预计欧洲在预测期内将出现盈利成长。欧洲各地激素避孕药的销售活跃且多样化。欧洲国家在避孕方面有不同的文化和法律实践，导致产品可得性、处方要求和使用模式各不相同。许多生产和销售荷尔蒙避孕药的大型製药企业也位于该地区。在欧洲国家，通常有多种避孕方法，包括口锭剂、贴片、环和植入。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球荷尔蒙避孕药市场：依产品类型

  • 介绍
  • 注射避孕药
  • 口服避孕药
  • 避孕环
  • 事后紧急避孕药
  • 经皮吸收贴片
  • 复方口服避孕药
  • 植入式避孕药
  • 在子宫内

第6章全球荷尔蒙避孕药市场：依荷尔蒙分类

  • 介绍
  • 雌激素
  • 雄激素
  • 促性腺激素
  • 黄体素
  • 抗雄激素
  • 其他荷尔蒙

第7章全球荷尔蒙避孕药市场：依年龄组

  • 介绍
  • 15-24岁
  • 25-34岁
  • 35-44岁
  • 44岁以上

第8章全球荷尔蒙避孕药市场：性别

  • 介绍
  • 女士
  • 男性

第9章全球荷尔蒙避孕药市场：依最终用户分类

  • 介绍
  • 家
  • 医院
  • 诊所
  • 零售药房
  • 其他最终用户

第10章全球荷尔蒙避孕药市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第11章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • Bayer Healthcare Pharmaceuticals
  • Amgen
  • Cipla Limited
  • Novartis AG
  • Glenmark Pharmaceuticals
  • Pfizer, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Piramal Healthcare Limited
  • Teva Pharmaceutical Industries
  • Abbvie Inc.
  • Organon group of companies.
  • Agile Therapeutics
  • Janssen Pharmaceutical, Inc.
  • Pregna International Limited
  • Pantarhei Bioscience
  • Mayne Pharma Group Limited
Product Code: SMRC24246

According to Stratistics MRC, the Global Hormonal Contraceptives Market is accounted for $18.3 billion in 2023 and is expected to reach $28.2 billion by 2030 growing at a CAGR of 6.3% during the forecast period. Birth control treatments that work on the endocrine system are called hormonal contraceptives. These techniques involve using hormones that women typically make, including progesterone and estrogen to stop ovulation and pregnancy. Hormonal contraception alters the uterus, decreasing the possibility of pregnancy. Hormonal contraceptives come in several forms, including skin-attached patches, pills, injections, arm implants, and intrauterine devices. These hormonal contraceptive methods are trustworthy and safe for preventing pregnancy. Over 99% of unwanted pregnancies are avoided when hormonal contraceptives are used.

According to the World Health Organization, modern contraception rose from 54% in 1990 to 57.4% in 2015 globally.

Market Dynamics:

Driver:

Rising global population

The world's population continues to grow, and this demographic trend has contributed to the increasing demand for effective birth control methods. Hormonal contraceptives have gained popularity due to their reversible nature, ease, and effectiveness in helping people control the size of their families and postpone or space out pregnancies. As individuals strive to achieve their desired family size and improve their socioeconomic conditions, access to effective contraception becomes crucial. These factors propel market demand.

Restraint:

Associated side effects

Potential drawbacks include thrush, or vaginal yeast infections, along with side effects like headaches, nausea, and sore breasts. In addition to causing mood swings and spotting in between periods, the hormones may lessen women's desire for sex. Additionally, there is a slight chance that blood clots (thrombosis) will form. Women who smoke, are extremely overweight, or have a family history of vascular disease are more likely to be at risk than women over 40. Therefore, these related drawbacks might hinder market expansion.

Opportunity:

Technological innovations

New and enhanced hormonal contraceptive methods have been made available as a result of advancements in pharmaceutical research and development. Low-dose formulations, long-acting reversible contraceptives (LARCs), including hormonal IUDs and contraceptive implants, and cutting-edge delivery methods like Trans dermal patches are some of them. Technological innovations have increased consumer choice and promoted market expansion.

Threat:

Regulatory policies and restrictions

The market may be severely impacted by laws and regulations limiting the supply and use of hormonal contraceptives. Hormonal contraception use is restricted or hindered in many countries due to strict rules or cultural and religious beliefs. However, these limitations may impede the expansion of the market and restrict the availability of hormonal contraceptives to those who require them.

COVID-19 Impact

Due to the drop in family planning and the necessity to avoid unwanted pregnancies during the pandemic, COVID-19 has had a little negative overall influence on the market for hormonal contraceptives. These contraceptives are mostly used in family planning. Clinic closures, appointment cancellations, and a shortage of healthcare practitioners may have restricted access to contraception, particularly hormonal contraceptives. This restriction on access might have led to a decline in the market for hormonal contraceptives or an increase in the use of less potent forms of birth control.

The oral contraceptive pills segment is expected to be the largest during the forecast period

The oral contraceptive pills segment is estimated to hold the largest share. OCPs have been available for a number of decades and are among the most popular types of hormonal contraceptives. Oral contraceptive pills are a popular option for people looking for dependable contraception because they are quite effective when used appropriately and consistently. They function by inhibiting ovulation, thickening cervical mucus, and weakening the uterine lining, all of which block sperm from getting to the egg. Oral contraceptive pills are taken daily; most formulations require 21 days of active pills, followed by a week of hormone-free or placebo pills.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to have lucrative growth during the forecast period. The main factors contributing to segmental growth are the expanding unmet need for these hormonal forms of contraception, women's preference for irreversible contraception in emerging economies, the introduction of innovative intrauterine devices by corporations like Allergen and Bayer AG, and the development of multispecialty hospitals. Furthermore, due to the increasing investment in hospital pharmacy improvement, particularly in developing nations.

Region with largest share:

North America commanded the largest market share during the extrapolated period due to factors like the high rate of hormonal contraception uptake, the strong presence of industry players in the area, and superior healthcare infrastructure. Hormonal contraceptives have a well-established organization in North America. The region benefits from a high level of acceptance and knowledge of contraceptive methods and reasonably simple access to hormonal contraceptives via pharmacies and healthcare practitioners. A variety of contraceptive methods, such as oral tablets, patches, injections, and intrauterine devices (IUDs), are available in the North American market.

Region with highest CAGR:

Europe is expected to witness profitable growth over the projection period. Hormonal contraception sales are thriving and varied across Europe. Different European nations have different cultural and legal conventions around contraception, which causes variations in the availability of the product, prescription requirements, and patterns of use. Major pharmaceutical businesses that produce and market hormonal contraceptives are also heavily represented in the region. A variety of contraceptive techniques, such as oral tablets, patches, rings, and implants, are usually available in European countries.

Key players in the market

Some of the key players in the Hormonal Contraceptives Market include: Bayer Healthcare Pharmaceuticals, Amgen, Cipla Limited, Novartis AG, Glenmark Pharmaceuticals, Pfizer, Inc., Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Piramal Healthcare Limited, Teva Pharmaceutical Industries, Abbvie Inc., Organon group of companies, Agile Therapeutics, Janssen Pharmaceutical, Inc., Pregna International Limited, Pantarhei Bioscience and Mayne Pharma Group Limited.

Key Developments:

In May 2021, Pantarhei Bioscience made an announcement that the company got the approval for new oral contraceptive Estelle from the European Commission. With the approval of Estelle, contraceptive can be marketed in all the European states.

In April 2021, Mayne Pharma Group Limited and Mithra Pharmaceuticals announced the approval by U.S Food and Drug Administration (FDA) for oral contraceptive NEXTSTELLIS. It is the only contraceptive pill containing estetrol, which is produced from a plant source.

Product Types Covered:

  • Injectable Birth Control
  • Oral Contraceptive Pills
  • Vaginal Rings
  • Emergency Contraceptive Pills
  • Transdermal Patches
  • Combined Oral Contraceptives
  • Implanted Contraceptives
  • Intrauterine

Hormones Covered:

  • Estrogens
  • Androgens
  • Gonadotropins
  • Progestogens
  • Antiandrogens
  • Other Hormones

Age Groups Covered:

  • 15 To 24 Years
  • 25 To 34 Years
  • 35 To 44 Years
  • Above 44 Years

Genders Covered:

  • Female
  • Male

End Users Covered:

  • Household
  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hormonal Contraceptives Market, By Product Type

  • 5.1 Introduction
  • 5.2 Injectable Birth Control
  • 5.3 Oral Contraceptive Pills
  • 5.4 Vaginal Rings
  • 5.5 Emergency Contraceptive Pills
  • 5.6 Transdermal Patches
  • 5.7 Combined Oral Contraceptives
  • 5.8 Implanted Contraceptives
  • 5.9 Intrauterine

6 Global Hormonal Contraceptives Market, By Hormone

  • 6.1 Introduction
  • 6.2 Estrogens
  • 6.3 Androgens
  • 6.4 Gonadotropins
  • 6.5 Progestogens
  • 6.6 Antiandrogens
  • 6.7 Other Hormones

7 Global Hormonal Contraceptives Market, By Age Group

  • 7.1 Introduction
  • 7.2 15 To 24 Years
  • 7.3 25 To 34 Years
  • 7.4 35 To 44 Years
  • 7.5 Above 44 Years

8 Global Hormonal Contraceptives Market, By Gender

  • 8.1 Introduction
  • 8.2 Female
  • 8.3 Male

9 Global Hormonal Contraceptives Market, By End User

  • 9.1 Introduction
  • 9.2 Household
  • 9.3 Hospitals
  • 9.4 Clinics
  • 9.5 Retail Pharmacies
  • 9.6 Other End Users

10 Global Hormonal Contraceptives Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Bayer Healthcare Pharmaceuticals
  • 12.2 Amgen
  • 12.3 Cipla Limited
  • 12.4 Novartis AG
  • 12.5 Glenmark Pharmaceuticals
  • 12.6 Pfizer, Inc.
  • 12.7 Lupin Pharmaceuticals, Inc.
  • 12.8 Sun Pharmaceutical Industries Ltd.
  • 12.9 Piramal Healthcare Limited
  • 12.10 Teva Pharmaceutical Industries
  • 12.11 Abbvie Inc.
  • 12.12 Organon group of companies.
  • 12.13 Agile Therapeutics
  • 12.14 Janssen Pharmaceutical, Inc.
  • 12.15 Pregna International Limited
  • 12.16 Pantarhei Bioscience
  • 12.17 Mayne Pharma Group Limited

List of Tables

  • Table 1 Global Hormonal Contraceptives Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Hormonal Contraceptives Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Hormonal Contraceptives Market Outlook, By Injectable Birth Control (2021-2030) ($MN)
  • Table 4 Global Hormonal Contraceptives Market Outlook, By Oral Contraceptive Pills (2021-2030) ($MN)
  • Table 5 Global Hormonal Contraceptives Market Outlook, By Vaginal Rings (2021-2030) ($MN)
  • Table 6 Global Hormonal Contraceptives Market Outlook, By Emergency Contraceptive Pills (2021-2030) ($MN)
  • Table 7 Global Hormonal Contraceptives Market Outlook, By Transdermal Patches (2021-2030) ($MN)
  • Table 8 Global Hormonal Contraceptives Market Outlook, By Combined Oral Contraceptives (2021-2030) ($MN)
  • Table 9 Global Hormonal Contraceptives Market Outlook, By Implanted Contraceptives (2021-2030) ($MN)
  • Table 10 Global Hormonal Contraceptives Market Outlook, By Intrauterine (2021-2030) ($MN)
  • Table 11 Global Hormonal Contraceptives Market Outlook, By Hormone (2021-2030) ($MN)
  • Table 12 Global Hormonal Contraceptives Market Outlook, By Estrogens (2021-2030) ($MN)
  • Table 13 Global Hormonal Contraceptives Market Outlook, By Androgens (2021-2030) ($MN)
  • Table 14 Global Hormonal Contraceptives Market Outlook, By Gonadotropins (2021-2030) ($MN)
  • Table 15 Global Hormonal Contraceptives Market Outlook, By Progestogens (2021-2030) ($MN)
  • Table 16 Global Hormonal Contraceptives Market Outlook, By Antiandrogens (2021-2030) ($MN)
  • Table 17 Global Hormonal Contraceptives Market Outlook, By Other Hormones (2021-2030) ($MN)
  • Table 18 Global Hormonal Contraceptives Market Outlook, By Age Group (2021-2030) ($MN)
  • Table 19 Global Hormonal Contraceptives Market Outlook, By 15 To 24 Years (2021-2030) ($MN)
  • Table 20 Global Hormonal Contraceptives Market Outlook, By 25 To 34 Years (2021-2030) ($MN)
  • Table 21 Global Hormonal Contraceptives Market Outlook, By 35 To 44 Years (2021-2030) ($MN)
  • Table 22 Global Hormonal Contraceptives Market Outlook, By Above 44 Years (2021-2030) ($MN)
  • Table 23 Global Hormonal Contraceptives Market Outlook, By Gender (2021-2030) ($MN)
  • Table 24 Global Hormonal Contraceptives Market Outlook, By Female (2021-2030) ($MN)
  • Table 25 Global Hormonal Contraceptives Market Outlook, By Male (2021-2030) ($MN)
  • Table 26 Global Hormonal Contraceptives Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Hormonal Contraceptives Market Outlook, By Household (2021-2030) ($MN)
  • Table 28 Global Hormonal Contraceptives Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 29 Global Hormonal Contraceptives Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 30 Global Hormonal Contraceptives Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 31 Global Hormonal Contraceptives Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.